Real-World study checks tafamidis for rare heart disease in korea

NCT ID NCT06321523

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how well the drug tafamidis 61mg works for Korean patients with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Researchers tracked 13 patients who were already prescribed the drug in real-world clinics. They measured changes in heart function, symptoms, and lab tests over time to see if the medicine helped manage the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tafamidis 61mg
What this could lead to: If results are positive, this could confirm that tafamidis helps manage ATTR-CM in Korean patients, supporting its use in this population.
What could go wrong: This was a very small study (13 people) with no comparison group, so results may not apply broadly. It also only looked at people already taking the drug, which can bias findings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

Contacts and locations

Locations

Gangnam Severance Hospital

Seoul, 06273, South Korea
Pusan National University Hospital

Busan, 49241, South Korea
Samsung Medical Center

Seoul, Seoul-teukbyeolsi [seoul], 06351, South Korea
Severance Hopital, Yonsei University Health System

Seoul, Seoul-teukbyeolsi [seoul], 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.